Monopar Therapeutics MNPR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$14.98M-9.2% | -$13.72M+29.4% | -$19.44M-12.3% | -$17.31M-4.5% | -$16.57M-6.3% | ||
| $5.18M+7.0% | $4.84M+20.6% | $4.01M+28.9% | $3.11M+43.6% | $2.17M+90.0% | ||
| -$10.01M+17.9% | -$12.2M-12.7% | -$10.83M-10.4% | -$9.81M+5.8% | -$10.41M-62.6% | ||
| -$68.71M-8.3% | -$63.45M-307% | -$15.6M-24.9% | -$12.49M+8.7% | -$13.68M+4.6% | ||
| $91.87M-0.1% | $91.96M-37.9% | $148.1M— | —— | —— | ||
| —— | —— | $121.66M+264% | $33.38M+4.6% | $31.9M-17.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Monopar Therapeutics generate?
- Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.
- Where does Monopar Therapeutics's cash flow data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.